BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
CV Sciences, Inc. CVSI
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$13.8M
▼ 12.2% vs FY2024
EPS · FY25
$-0.01
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-58.7%
Net margin · FY25
-6.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 13.8M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 7 cents on every revenue dollar this year.
Per share
USD -0.01
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-58.7%
Return on equity, FY2025
ROE
Operating margin-3.4%
Net margin-6.9%
Return on assets-12.9%
Each USD of equity lost 59 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−10.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−5.2%
−10.8%
+1.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.18B
Shares outstanding, FY2025
Change, 5 years+83.0%
Change, 10 years—
The share count grew 83% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.0M
total assets, end of FY2025
Total assetsUSD 7.0M
EquityUSD 1.5M
CashUSD 278,000.00
Gross debtUSD 1.6M
Net debtUSD 1.4M
Current ratio1.03×
Net debt stands at 93% of equity.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.01
−0.01
0.02
−0.07
−0.14
−0.22
−0.17
0.09
−0.06
−0.27
−0.35
·
−0.23
−0.01
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−58.7
−101.9
291.8
−593.9
−210.8
−110.4
−56.1
43.0
−33.1
−77.5
−55.2
−8.9
−55.4
·
·
Shares out B
0.18
0.18
0.16
0.15
0.11
0.10
0.10
0.09
0.09
0.06
0.05
0.03
0.02
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed